Form 4: Oruka Therapeutics Director Acquires 116,483 Shares

Oruka Therapeutics Director Carl Dambkowski reported the acquisition of 116,483 shares of common stock through a pro-rata distribution from an LLC.

Summary

• Carl Dambkowski, a Director of Oruka Therapeutics, Inc. (ORKA), acquired 116,483 shares of the company's common stock.
• The transaction occurred on January 23, 2026.
• The shares were obtained through a pro-rata distribution from a limited liability company in which Dambkowski is a member, with no consideration paid.
• Following this transaction, Dambkowski directly beneficially owns 116,483 shares of Oruka Therapeutics common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine insider ownership change via an internal pro-rata distribution for no consideration, rather than a market purchase or sale, indicating a neutral impact on company valuation or future prospects.

Positives

• Director Carl Dambkowski increased his direct beneficial ownership of Oruka Therapeutics common stock by 116,483 shares, which can be seen as a minor positive signal of alignment.

Future Outlook

NA

Industry Context

This filing is specific to Oruka Therapeutics and its director's ownership, and does not provide broader industry context or trends.

Related Party Transactions

• The acquisition of 116,483 shares of common stock by Director Carl Dambkowski was a pro-rata distribution from a limited liability company in which he is a member, for no consideration.

Stakeholder Impact

• Shareholders: The increase in direct beneficial ownership by a director may be viewed as a minor positive signal of management alignment with shareholder interests.

Key Dates

Recommendation

This Form 4 reports an internal transfer of shares to a director's direct beneficial ownership for no consideration, not a market transaction. Such an event typically does not provide new information warranting a change in investment recommendation, as it doesn't reflect a new investment decision based on company performance or a significant shift in market sentiment.

Keywords

Oruka Therapeutics, ORKA, Carl Dambkowski, Form 4, insider transaction, beneficial ownership, common stock, director, equity distribution